To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

• Status: Unknown status
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Treatments: Lobeline

Criteria

Inclusion Criteria:

• Healthy individuals with a body mass index between 18 and 30.

• Willing and able to give written consent.

• Must have a negative drug test

• Females must have a negative pregnancy test prior to study drug administration

• Must have no medical contraindications as determined by routine testing

Exclusion Criteria:

• Please contact the site for more information